Corporate News Dermapharm Holding SE hits upper end of guidance range for adjusted EBITDA, primarily due to steadily growing international presence in branded business Consolidated revenue up 10.8% year on year to EUR 1,135.4 million Adjusted consolidated EBITDA declines by 13.8% to EUR 310.2 million Adjusted consolidated EBITDA margin: 27.3% [...]

This is an abstract of the document. To keep reading, click here and get access to the original version.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Dermapharm Holding SE published this content on 13 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 April 2024 09:40:01 UTC.